Endometrial Cancer Market 2019 Industry Trends, Leading Players: Bristol-Myers Squibb Company, Pfizer, R-Pharm-US LLC, Elekta AB, and Varian Medical Systems

The global endometrial cancer market is expected to register a CAGR of 4.5% over the forecast period. Factors responsible for the growth of this market include a rise in awareness about uterine diseases and their available therapies, innovation in drug development and subsequent technological advancements, and increasing healthcare expenditure. For instance, in most countries, the rate at which healthcare expenditure is increasing is higher than the rate of economic growth, and this is a trend that has been observed over the decades. The presence of equitable, responsive, and efficient health systems across the countries of North America, Europe, and Asia-Pacific has also contributed to the maximum share of GDP being utilized as healthcare expenditure. Moreover, with the increase in the number of people diagnosed with cancer, the introduction of new therapies is expected to increase the costs of cancer care. Cancer treatment can be very expensive, especially with the patients and survivors often needing long-term treatment and monitoring. Additionally, attractive healthcare insurance plans and better reimbursement rates play a vital role in increasing people’s expenditure on treatments, which is expected to drive the market studied.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/19791
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

However, factors, such as the adverse effects of the treatment and high toxicity of drugs are expected to hinder the market growth.

Scope of the Report
Endometrial cancer is the malignancy that develops in the layers of the cells that form the endometrium, the lining of the uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of being affected by endometrial cancer.

Competitive Landscape
The endometrial cancer market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Due to the rising prevalence of cancer, there are several products in the trails; henceforth, it is expected that few other smaller players may enter into the market. Some of the major players of the market are Bristol-Myers Squibb Company, Pfizer Inc., R-Pharm-US LLC, Elekta AB, and Varian Medical Systems, Inc., among others.

Request Discount on this report @ https://marketprognosis.com/discount-request/19791
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

North America dominates the Market and expected to do Same in the Forecast Period
North America currently dominates the market for endometrial cancer and is expected to continue its stronghold for a few more years due to a high incidence of uterine serous carcinoma. In North America, the United States holds the largest market share. This can be majorly attributed to increasing prevalence rates of endometrial cancers. For instance, according to the American Cancer Society, it is estimated that in 2019, approximately 61,880 new cases of cancer of the uterus will be diagnosed in the United States. This, along with other factors, such as the rising awareness for the diagnosis of cancer and the presence of the developed healthcare infrastructure are expected to propel the market in the United States.

Key Market Trends
Chemotherapy is expected to hold the Highest Revenue Share in the Type of Therapy Segmentation
In the global endometrial cancer market, the chemotherapy segment is expected to witness a moderate CAGR, owing to the lesser number of drugs approved for the treatment of endometrial cancer. However, the segment is expected to hold the largest share in the type of therapy; this is due to the high adoption rate of chemotherapy when compared to radiation and surgical treatment. Besides, the chemotherapeutic agents, such as carboplatin and paclitaxel, are commonly recommended as the first line of therapy in the majority of the cancer cases, which increases demand for these products. For example, recently the US FDA approved the IXEMPRA (ixabepilone) for use in the treatment of endometrial cancer and this is expected to drive the growth of the market.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/19791
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.